Downstream of S1P1, etrasimod showed similar potency to other S1P receptor modulators in promoting β‐arrestin recruitment and S1P1 internalization but was less potent in G protein activation, which may contribute to its favorable benefit–risk profile in treating conditions such as ulcerative colitis. Here, S1PR1 is linked to ulcerative colitis.